US2013210722A1PendingUtilityA1
Methods for using peptide agonists having glp-1 activity
Est. expiryJul 12, 2019(expired)· nominal 20-yr term from priority
A61P 3/10A61P 3/04C07K 14/605A61K 47/62A61K 38/00A61K 38/26C07K 14/57563
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.
Claims
exact text as granted — not AI-modified1 . A method for treating type 2 diabetes mellitus in a subject in need thereof, said method comprising administering to said subject desPro 36 -exendin-4(1-39)-Lys 6 -NH 2 (SEQ ID NO: 93), or a pharmaceutically acceptable salt thereof in an amount that is effective for the treatment of type 2 diabetes mellitus.
Join the waitlist — get patent alerts
Track US2013210722A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.